Latest Content

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Recent studies suggest lithium may effectively prevent cognitive decline and Alzheimer disease, challenging the dominance of lecanemab in early dementia treatment.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Explore the transformative potential of futures thinking in mental health, offering innovative frameworks to navigate uncertainty and enhance agency.

Explore the evolving role of lamotrigine in treating bipolar depression, highlighting its benefits, risks, and recent clinical guidelines.

New analysis reveals that negative symptoms and stimulant use may predict positive responses to Cobenfy in schizophrenia treatment.

Two promising psychiatrists have tragically passed away.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.